Photo 1. Image related to CoRA, a circle of Willis-based detection method
- DEEPNOID’s research team to present its latest AI diagnostic technologies for cerebrovascular diseases in Türkiye in September 2025
- Research based on DEEP:NEURO on the segmentation of very small cerebral aneurysms and automated aneurysm localization draws attention at the European Society of Neuroradiology (ESNR)
- “Research exploring new ways to improve accuracy and efficiency in AI diagnosis of cerebrovascular diseases”
DEEPNOID, one of Korea’s first-generation medical AI companies (CEO Woo Sik Choi), announced on July 25, 2025, that six of its research abstracts on AI diagnostic technologies for cerebrovascular and brain parenchymal diseases had been accepted at ESNR 2025, the annual congress of the European Society of Neuroradiology.
Organized by the European Society of Neuroradiology (ESNR), the international congress will be held in Istanbul, Türkiye, from September 17 to 21, 2025. This year’s congress is co-hosted with the Asian-Oceanian Congress of Neuroradiology (AOCNR 2025) and the Turkish Society of Neuroradiology (TSNR 2025), bringing together leading neuroradiology experts from around the world to share the latest diagnostic techniques and research findings.
Two of the accepted abstracts relate to DEEP:NEURO, DEEPNOID’s AI solution for cerebral aneurysm image interpretation and diagnostic assistance. The first presents a context-aware semantic augmentation (CSA) technique that can precisely segment very small cerebral aneurysms of 3 mm or smaller. The second presents CoRA, an in-house detection method based on the circle of Willis that significantly improves the accuracy and practicality of cerebral aneurysm localization. Both studies will be presented as posters during the congress.
“This is a notable achievement in that the research sets a new technical standard in AI diagnosis of cerebrovascular diseases and explores ways to significantly improve the accuracy and efficiency of cerebral aneurysm diagnosis,” said Sungmin Ko, Head of Medical R&D Division at DEEPNOID. “As AI emerges as a key future technology in neuroradiology, I believe the research was well received because it delivers results that are meaningful for real-world clinical application.”
DEEP:NEURO was designated as an Innovative Medical Technology in 2023 and obtained a non-reimbursable billing code under Korea’s National Health Insurance in 2024. As of July 2025, it was installed at 37 hospitals in Korea and used in clinical practice.
###
